Drug Profile
Research programme: neurological disorders gene therapy - Proximagen Neuroscience
Alternative Names: prx 4001Latest Information Update: 15 Aug 2012
Price :
$50
*
At a glance
- Originator Proximagen Neuroscience
- Developer Proximagen
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 15 Aug 2012 Discontinued - Preclinical for Neurological disorders in United Kingdom (unspecified route)